BIOMAT Database Logo BIOMAT Database Logo

In vitro activity of LY146032 against gram-positive bacteria. 1988

M Silva, and N V Jacobus, and S L Gorbach
Department of Community Health, Tufts University School of Medicine, Boston, MA 02111.

The activity of LY146032 (LY) was evaluated against 269 clinical isolates: 150 Staphylococcus spp. (Staph), 45 enterococci, 51 Clostridium spp., and 23 peptostreptococci. LY was compared to penicillin, metronidazole, imipenem, clindamycin, oxacillin, ciprofloxacin, vancomycin, and ampicillin. LY and oxacillin were tested against Staph by microdilution in cation-supplemented Mueller-Hinton broth (CSMHB), and in unsupplemented Mueller-Hinton broth (MHB). For LY, the MIC 90s in CSMHB were 16-32 dilutions lower. Among the Staph, the MIC 90s for LY, vancomycin, and ciprofloxacin were 4 micrograms/ml, 4 micrograms/ml, and 2 micrograms/ml respectively. The MIC 90s for enterococci by agar dilution were as follows: LY 8 micrograms/ml; ampicillin 4 micrograms/ml; imipenem 4 micrograms/ml; vancomycin 4 micrograms/ml; and ciprofloxacin 2 micrograms/ml. Clindamycin and penicillin were the most effective drugs against peptostreptococci and Clostridia spp., but LY was the most active drug against Clostridium difficile. The bactericidal activity of LY was determined by 24-hr time-kill curves in MHB. These showed a bactericidal effect against enterococci, and a bacteriostatic effect against three of four strains of Staph. Synergy was demonstrated against enterococci and Staph when LY was tested with aztreonam, ceftriaxone, or tobramycin. LY is a promising new agent against gram-positive bacteria, including methicillin resistant strains of staphylococci and enterococci.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D003470 Culture Media Any liquid or solid preparation made specifically for the growth, storage, or transport of microorganisms or other types of cells. The variety of media that exist allow for the culturing of specific microorganisms and cell types, such as differential media, selective media, test media, and defined media. Solid media consist of liquid media that have been solidified with an agent such as AGAR or GELATIN. Media, Culture
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D006094 Gram-Positive Bacteria Bacteria which retain the crystal violet stain when treated by Gram's method. Gram Positive Bacteria
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D017576 Daptomycin A cyclic lipopeptide antibiotic that inhibits GRAM-POSITIVE BACTERIA. Cubicin,Daptomycin, 9-L beta-Aspartic Acid,Deptomycin,LY-146032,Daptomycin, 9 L beta Aspartic Acid,LY 146032,LY146032

Related Publications

M Silva, and N V Jacobus, and S L Gorbach
In vitro activity of a new cyclic lipopeptide antibiotic, LY146032, against gram-positive clinical bacteria.
March 1987, Antimicrobial agents and chemotherapy,
M Silva, and N V Jacobus, and S L Gorbach
Comparative in vitro activity of LY146032 (daptomycin) against gram-positive cocci.
February 1987, European journal of clinical microbiology,
M Silva, and N V Jacobus, and S L Gorbach
In vitro activity of LY146032 alone and in combination with other antibiotics against gram-positive bacteria.
February 1988, Antimicrobial agents and chemotherapy,
M Silva, and N V Jacobus, and S L Gorbach
In-vitro activity of LY146032 against gram-positive isolates from cancer patients.
October 1987, The Journal of antimicrobial chemotherapy,
M Silva, and N V Jacobus, and S L Gorbach
Comparative in-vitro activity of LY146032 and eight other antibiotics against gram-positive bacteria isolated from children.
August 1987, The Journal of antimicrobial chemotherapy,
M Silva, and N V Jacobus, and S L Gorbach
In vitro activity of LY146032, a new lipopeptide antibiotic, against gram-positive cocci.
February 1987, Antimicrobial agents and chemotherapy,
M Silva, and N V Jacobus, and S L Gorbach
In vitro activities of daptomycin (LY146032) and paldimycin (U-70,138F) against anaerobic gram-positive bacteria.
May 1988, Antimicrobial agents and chemotherapy,
M Silva, and N V Jacobus, and S L Gorbach
In vitro activity of fluoroquinolones against gram-positive bacteria.
January 1995, Drugs,
M Silva, and N V Jacobus, and S L Gorbach
In vitro activity of levofloxacin against gram-positive bacteria.
January 1999, Chemotherapy,
M Silva, and N V Jacobus, and S L Gorbach
In vitro activity of LY146032 (daptomycin) against selected aerobic bacteria.
February 1987, European journal of clinical microbiology,
Copied contents to your clipboard!